Kalvista Pharmaceuticals Inc (KALV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) has a cash flow conversion efficiency ratio of -1.923x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.68 Million) by net assets ($17.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Kalvista Pharmaceuticals Inc stock price for real-time trading data and today's change.
Kalvista Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Kalvista Pharmaceuticals Inc (KALV) market capitalisation for the company's overall valuation and market capitalisation.
Kalvista Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalvista Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Kalvista Pharmaceuticals Inc balance sheet assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Africa Oil Corp
TO:AOI
|
0.039x |
|
Judo Capital Holdings Ltd
AU:JDO
|
0.032x |
|
SMU S.A
SN:SMU
|
0.072x |
|
Wushang Group Co Ltd
SHE:000501
|
0.033x |
|
Zhejiang Zhongxin Fluoride Materials Co Ltd Class A
SHE:002915
|
-0.032x |
|
Aarti Pharmalabs Limited
NSE:AARTIPHARM
|
0.019x |
|
LightPath Technologies Inc
NASDAQ:LPTH
|
-0.060x |
|
BMC Medical Co. Ltd. A
SHE:301367
|
N/A |
Annual Cash Flow Conversion Efficiency for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Kalvista Pharmaceuticals Inc from 2013 to 2025. Review KALV financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $95.39 Million | $-152.91 Million | -1.603x | -271.10% |
| 2024-04-30 | $206.58 Million | $-89.23 Million | -0.432x | +7.58% |
| 2023-04-30 | $161.03 Million | $-75.26 Million | -0.467x | -10.72% |
| 2022-04-30 | $185.09 Million | $-78.13 Million | -0.422x | -259.85% |
| 2021-04-30 | $257.19 Million | $-30.17 Million | -0.117x | +78.08% |
| 2020-04-30 | $83.75 Million | $-44.82 Million | -0.535x | -42.35% |
| 2019-04-30 | $96.74 Million | $-36.37 Million | -0.376x | -197.03% |
| 2018-04-30 | $27.25 Million | $10.56 Million | 0.387x | +151.16% |
| 2017-04-30 | $31.33 Million | $-23.72 Million | -0.757x | -23.73% |
| 2016-04-30 | $21.50 Million | $-13.16 Million | -0.612x | -418.50% |
| 2016-03-31 | $43.07 Million | $-5.08 Million | -0.118x | +72.10% |
| 2015-12-31 | $49.31 Million | $-20.86 Million | -0.423x | -393.54% |
| 2015-04-30 | $-44.18 Million | $-6.37 Million | 0.144x | -94.08% |
| 2014-12-31 | $-4.62 Million | $-11.25 Million | 2.433x | +1588.23% |
| 2014-04-30 | $-33.71 Million | $-4.86 Million | 0.144x | +122.15% |
| 2013-04-30 | $-28.29 Million | $-1.83 Million | 0.065x | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more